Beauty Just Went All-In on Supplements. Now Comes the Hard Part.

For years, "beauty from within" was a niche shelf, a few collagen powders and hair-and-nails gummies parked next to the moisturisers. In 2026, it became a boardroom priority.

The signals are impossible to ignore. In August, Procter & Gamble agreed to acquire the science-led supplement brand Thorne for $3.8 billion less than three years after L Catterton took it private for a reported ~$680 million. Unilever Ventures has taken a stake in the longevity supplement brand NOVOS. Across the DACH region and beyond, private capital is assembling supplement platforms at a pace that would have seemed fantastical eighteen months ago. When the biggest names in beauty and consumer health start writing cheques this size, they aren't chasing a trend, they're repositioning around a new category.

And it isn't only the acquirers. Nearly every brand we speak with is quietly or loudly adding an ingestible layer to its skincare stack. Serums now come with capsules. Clinics pair topicals with biomarker panels. The line between what you put on your skin and what you put in your body is dissolving, and a single question is driving it: if ageing is biological, why would we only treat it at the surface?

Beauty, nutrition and longevity are becoming one ecosystem

This is bigger than a product-line extension. Beauty, functional nutrition and longevity science are merging into one consumer health ecosystem, and the centre of gravity is moving from products to protocols - ongoing, personalised routines that combine topical, ingestible, diagnostic and behavioural elements into something a person actually follows over time.

That's a genuinely exciting future. It's also a much harder one to win in. Launching a supplement has never been easier; a nice brand, a few influencers and a Shopify store will get you to market in weeks. Building relevance, trust and repeat purchase has never been harder. The barrier to entry has collapsed; the barrier to credibility has gone up.

The pain points nobody has solved yet

As the money and the momentum arrive, so do the problems. Here is what we hear most often from both sides of the counter.

For brands, the challenge is proving it. Efficacy is fast becoming the price of entry, not a differentiator and that raises hard questions most beauty companies have never had to answer. Where is the evidence? What's the right dose, and is it actually the dose in the capsule? Is the active bioavailable, or does it pass straight through? Who owns the regulatory risk when a skincare company starts making ingestible claims across different markets? Growing revenue at 40% a year is one thing; growing the science, quality systems and operational rigour to match it is another entirely. The brands that last will connect science, formulation, data, community and distribution, not just marketing.

For consumers, the challenge is trust. Shoppers are more interested in their own biology than ever, but they are also more lost. The shelf is crowded, the claims are loud and often contradictory, and there is no easy way to tell a rigorously formulated product from a well-marketed one. What is actually good for me? What's a quality product versus clever packaging? What's worth the money, and what's just hope in a bottle? Without clear answers, misinformation fills the gap, and every unsubstantiated “reverse your age” claim erodes trust in the serious science happening alongside it.

This is the paradox of the moment: the category has never had more investment, more attention or more consumer appetite, and it has never been more confusing.

Why we're covering this at INNOCOS Zurich

We built the INNOCOS agenda around exactly this inflexion point, because these are the questions that will decide who wins the next decade and they deserve a room full of the people equipped to answer them.

At INNOCOS Zurich (9–11 September), Mintel's Global VP of Wellness Insights, Nicole Bensi, opens the conversation with "Winning the Future of Wellness: The New Rules of Competition", a look at why efficacy is becoming the price of entry and why prediction is starting to replace personalisation. From there, our panel "From Products to Protocols: The Next Evolution of Consumer Health" digs into what it really takes to move beyond standalone products toward sustained, personalised health outcomes and the ecosystem required to help consumers turn intention into behaviour.

It's also the thinking behind our Beauty & Longevity CHOICE Awards, where we judge nominations first and foremost on the science presented behind their claims. In a category drowning in noise, we think the most useful thing an industry event can do is insist on the evidence.

The supplement wave in beauty is real, and it's only accelerating. The opportunity now is to grow it responsibly to build a category consumers can trust, on foundations of evidence, quality and honest claims. That's the conversation we're bringing to Zurich, and we'd love for you to be part of it.

Join us at INNOCOS Zurich, 9–11 September. Reserve your place at www.innocosevents.com

Sources: P&G to acquire Thorne for $3.8B (CNBC) · Thorne press release · Unilever Ventures invests in NOVOS (BeautyMatter)